Valvular Heart Disease Clinical Trials

As a patient at Cedars-Sinai, you will have access to the latest clinical trials and research for valvular heart disease. Backed by a respected team of specialists and researchers, our clinical trials aim to further the advancement of diagnosing and treating your condition.

Questions? See the Clinical Trials FAQs.

ACURATE IDE: Safety and Efficacy Study of Acurate Valve for Transcatheter Aortic Valve Replacement

Condition: 

Aortic Stenosis

Assessment of Transcatheter and Surgical Aortic Bioprosthetic Valve Thrombosis and Its Treatment With Anticoagulation (RESOLVE)

Condition: 

Prosthetic Valve Thrombosis

Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO)

Condition: 

Stroke

Caisson Transcatheter Mitral Valve Replacement (TMVR) System Early Feasibility Study (PRELUDE)

Condition: 

Mitral Valve Regurgitation

Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) (COAPT)

Condition: 

Mitral Regurgitation, Mitral Valve Regurgitation, Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects, Heart Failure

The CLASP Study Edwards PASCAL Transcatheter Mitral Valve Repair System Study (CLASP)

Condition: 

Mitral Valve Regurgitation

Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT)

Condition: 

Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease (Heart), Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease

DEF-315 Better Accuracy in EF Assessment With DEFINITY (BENEFIT2)

Condition: 

Cardiac Disease

Early Feasibility Study of the Edwards FORMA Tricuspid Transcatheter Repair System

Condition: 

Tricuspid Valve Regurgitation

Early Feasibility Study for the Foldax Tria Aortic Heart Valve

Condition: 

Aortic Valve Disease, Aortic Valve Stenosis

Early Feasibility Study of the Percutaneous 4Tech TriCinch Coil Tricuspid Valve Repair System

Condition: 

Functional Tricuspid Regurgitation, Heart Valve Diseases, Tricuspid Valve Insufficiency

Edwards Cardioband System ACTIVE Pivotal Clinical Trial

Condition: 

Functional Mitral Regurgitation, Mitral Regurgitation, Mitral Insufficiency

Condition: 

Atrial Fibrillation

Key Inclusion Criteria:

  • Successful TAVI via transvascular access routes such as femoral and subclavian arteries
  • Indication for chronic oral anticoagulation (blood thinning medication taken by mouth)
  • At least 18 years old

Summary:

The purpose of this study is to examine the safety and effectiveness of an anticoagulant drug called edoxaban versus other anticoagulants (blood thinning medication) in patients who have undergone transcatheter aortic valve implantation (TAVI) and who suffer from atrial fibrillation (irregular heart rate).

Evaluation of Transcatheter Aortic Valve Replacement Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis (EARLY TAVR)

Condition: 

Aortic Stenosis, Heart Diseases

Condition: 

Aortic stenosis

Key Inclusion Criteria:

  • Severe, calcific aortic stenosis
  • New York Heart Association functional class ≥II
  • At intermediate risk for open surgical therapy

Summary:

The purpose of this study is to evaluate the safety and effectiveness of an investigational device called Edwards CENTERA Transcatheter Heart Valve System (THV)- Model 9551 in patients with symptomatic, severe, calcific aortic stenosis who are at intermediate operative risk for surgical aortic valve replacement. Aortic stenosis is a critical narrowing of the aortic valve. Participants in this study will have a procedure called transcatheter aortic valve replacement (TAVR) using the CENTERA THV (rather than one of the valves that is usually used for TAVR).

JenaValve Pericardial TAVR Aortic Regurgitation Study

Condition: 

Aortic Regurgitation

Mitral Implantation of Transcatheter Valves (MITRAL)

Condition: 

Mitral Valve Disease

Multicenter Study of Congenital Pulmonic Valve Dysfunction Studying the SAPIEN 3 THV With the Alterra Adaptive Prestent (ALTERRA)

Condition: 

Pulmonary Disease, Transpulmonary Valve Replacement, Pulmonary Stenosis, TPVR, Tetralogy of Fallot, Congenital Heart Disease

NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation

Condition: 

Mitral Valve Failure

The PARTNER 3 - Trial - The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis (P3)

Condition: 

Aortic Stenosis

Real World Expanded Multicenter Study of the MitraClip® System (REALISM)

Condition: 

Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation, Mitral Insufficiency

The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation

Condition: 

Symptomatic Aortic Stenosis

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI)

Condition: 

Severe Aortic Stenosis

Condition: 

Aortic stenosis, heart failure, aortic insufficiency

Key Inclusion Criteria:

  • New York Heart Association Class ≥2
  • NT-proBNP >1500 pg/mL (or BNP >400 pg/mL) or hospitalization for heart failure within the last year
  • Under appropriate guideline-directed heart failure therapy for a minimum of three months

Summary:

This study focuses on patients with heart failure (HF) who have moderate aortic stenosis (AS). The purpose of the study is to compare the safety and effectiveness of transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3 transcatheter heart valve (THV) and optimal heart failure therapy (OHFT) versus OHFT alone in HF patients with moderate AS. OHFT is defined as guideline-directed medical therapy (medication only or a combination of medical therapy and approved heart failure devices).